Skip to main content
SpringerLink
Log in

Pathology of Lung Cancer

  • Chapter
  • First Online:
Advances in Radiation Oncology in Lung Cancer

Part of the book series: Medical Radiology ((Med Radiol Radiat Oncol))

  • 1799 Accesses

Abstract

Over the past decade, the diagnosis, treatment and management of lung cancer has evolved substantially, in large part to the development of novel chemotherapeutic agents and targeted therapy in particular. As such, accurate classification of lung carcinomas from a histologic standpoint has become increasingly critical for appropriate patient management. Much of the focus of lung cancer pathology in the past decade has concentrated on adenocarcinoma. As such, the aim of this chapter will primarily focus on the evolution of this cancer subtype and review the recently published adenocarcinoma classification prepared jointly by the International Association for the Study of Lung Cancer, the American Thoracic Society and the European Respiratory Society. Squamous cell carcinoma will also be discussed, particularly in regard to accurate discrimination from adenocarcinoma. The role of the pathologist in molecular testing will be reviewed, particularly as it relates to specimens obtained from radiologic procedures. Finally, given that the scope of this publication is radiation oncology, the histologic changes and evaluation of tumors which have undergone radiation and/or neo-adjuvant therapy will be discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Amin MB, Tamboli P et al (2002) Micropapillary component in lung adenocarcinoma: a distinctive histologic feature with possible prognostic significance. Am J Surg Pathol 26(3):358–364

    Article  PubMed  Google Scholar 

  • Beasley MB, Brambilla E et al (2005) The 2004 World Health Organization classification of lung tumors. Semin Roentgenol 40(2):90–97

    Article  PubMed  Google Scholar 

  • Borczuk AC (2009) Micropapillary histology: a frequent morphology of mutation-associated lung adenocarcinoma? Am J Clin Pathol 131(5):615–617

    Article  PubMed  Google Scholar 

  • Borczuk AC, Qian F et al (2009) Invasive size is an independent predictor of survival in pulmonary adenocarcinoma. Am J Surg Pathol 33(3):462–469

    Article  PubMed  Google Scholar 

  • Brownlee NA, Mott RT et al (2005) Mucinous (colloid) adenocarcinoma of the lung. Arch Pathol Lab Med 129(1):121–122

    PubMed  Google Scholar 

  • Camilo R, Capelozzi VL et al (2006) Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas. Hum Pathol 37(5):542–546

    Article  PubMed  CAS  Google Scholar 

  • Cohen MH, Gootenberg J et al (2007) FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12(6):713–718

    Article  PubMed  CAS  Google Scholar 

  • Copin MC, Buisine MP et al (2001) Mucinous bronchioloalveolar carcinomas display a specific pattern of mucin gene expression among primary lung adenocarcinomas. Hum Pathol 32(3):274–281

    Article  PubMed  CAS  Google Scholar 

  • Dacic S (2008) EGFR assays in lung cancer. Adv Anat Pathol 15(4):241–247

    Article  PubMed  CAS  Google Scholar 

  • Dacic S, Shuai Y et al (2010) Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. Mod Pathol 23(2):159–168

    Article  PubMed  CAS  Google Scholar 

  • Douillard JY, Shepherd FA et al (2010) Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 28(5):744–752

    Article  PubMed  CAS  Google Scholar 

  • Finberg KE, Sequist LV et al (2007) Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn 9(3):320–326

    Article  PubMed  CAS  Google Scholar 

  • Gillespie JW, Best CJ et al (2002) Evaluation of non-formalin tissue fixation for molecular profiling studies. Am J Pathol 160(2):449–457

    Article  PubMed  CAS  Google Scholar 

  • Hata A, Katakami N et al (2010) Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma. J Thorac Oncol 5(8):1197–1200

    Article  PubMed  Google Scholar 

  • Hoshi R, Tsuzuku M et al (2004) Micropapillary clusters in early-stage lung adenocarcinomas: a distinct cytologic sign of significantly poor prognosis. Cancer 102(2):81–86

    Article  PubMed  Google Scholar 

  • Inamura K, Satoh Y et al (2005) Pulmonary adenocarcinomas with enteric differentiation: histologic and immunohistochemical characteristics compared with metastatic colorectal cancers and usual pulmonary adenocarcinomas. Am J Surg Pathol 29(5):660–665

    Article  PubMed  Google Scholar 

  • Junker K, Thomas M et al (1997a) Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment. J Cancer Res Clin Oncol 123(9):469–477

    Article  CAS  Google Scholar 

  • Junker K, Thomas M et al (1997b) [Regression grading of neoadjuvant non-small-cell lung carcinoma treatment]. Pathologe 18(2):131–140

    Article  CAS  Google Scholar 

  • Junker K, Langner K et al (2001) Grading of tumor regression in non-small cell lung cancer : morphology and prognosis. Chest 120(5):1584–1591

    Article  PubMed  CAS  Google Scholar 

  • Kamiya K, Hayashi Y et al (2008) Histopathological features and prognostic significance of the micropapillary pattern in lung adenocarcinoma. Mod Pathol 21(8):992–1001

    Article  PubMed  CAS  Google Scholar 

  • Kargi A, Gurel D et al (2007) The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol 15(4):415–420

    Article  PubMed  CAS  Google Scholar 

  • Kawakami T, Nabeshima K et al (2007) Micropapillary pattern and grade of stromal invasion in pT1 adenocarcinoma of the lung: usefulness as prognostic factors. Mod Pathol 20(5):514–521

    Article  PubMed  Google Scholar 

  • Kuroda N, Hamaguchi N et al (2006) Lung adenocarcinoma with a micropapillary pattern: a clinicopathological study of 25 cases. APMIS 114(5):381–385

    Article  PubMed  CAS  Google Scholar 

  • Lim E, Goldstraw P et al (2008) Proceedings of the IASLC International Workshop on Advances in Pulmonary Neuroendocrine Tumors 2007. J Thorac Oncol 3(10):1194–1201

    Article  PubMed  Google Scholar 

  • Liu-Jarin X, Stoopler MB et al (2003) Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy. Mod Pathol 16(11):1102–1108

    Article  PubMed  Google Scholar 

  • Loo PS, Thomas SC et al (2010) Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol 5(4):442–447

    Article  PubMed  Google Scholar 

  • Maemondo M, Inoue A et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380–2388

    Article  PubMed  CAS  Google Scholar 

  • Makimoto Y, Nabeshima K et al (2005) Micropapillary pattern: a distinct pathological marker to subclassify tumours with a significantly poor prognosis within small peripheral lung adenocarcinoma (</=20 mm) with mixed bronchioloalveolar and invasive subtypes (Noguchi’s type C tumours). Histopathology 46(6):677–684

    Article  PubMed  CAS  Google Scholar 

  • Mitsudomi T, Kosaka T et al (2005) Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23(11):2513–2520

    Article  PubMed  CAS  Google Scholar 

  • Mitsudomi T, Morita S et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2):121–128

    Article  PubMed  CAS  Google Scholar 

  • Miyoshi T, Satoh Y et al (2003) Early-stage lung adenocarcinomas with a micropapillary pattern, a distinct pathologic marker for a significantly poor prognosis. Am J Surg Pathol 27(1):101–109

    Article  PubMed  Google Scholar 

  • Mok TS, Wu YL et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947–957

    Article  PubMed  CAS  Google Scholar 

  • Nicholson AG, Gonzalez D et al (2010) Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol 5(4):436–441

    Article  PubMed  Google Scholar 

  • Noguchi M, Morikawa A et al (1995) Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 75(12):2844–2852

    Article  PubMed  CAS  Google Scholar 

  • Pirker R, Herth FJ et al (2010) Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol 5(10):1706–1713

    Article  PubMed  Google Scholar 

  • Rekhtman N, Brandt SM et al (2011) Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol 6(3):451–458

    Article  PubMed  Google Scholar 

  • Rodig SJ, Mino-Kenudson M et al (2009) Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 15(16):5216–5223

    Article  PubMed  CAS  Google Scholar 

  • Rossi G, Murer B et al (2004) Primary mucinous (so-called colloid) carcinomas of the lung: a clinicopathologic and immunohistochemical study with special reference to CDX-2 homeobox gene and MUC2 expression. Am J Surg Pathol 28(4):442–452

    Article  PubMed  Google Scholar 

  • Sakurai H, Dobashi Y et al (2004a) Bronchioloalveolar carcinoma of the lung 3 centimeters or less in diameter: a prognostic assessment. Ann Thorac Surg 78(5):1728–1733

    Article  PubMed  Google Scholar 

  • Sakurai H, Maeshima A et al (2004b) Grade of stromal invasion in small adenocarcinoma of the lung: histopathological minimal invasion and prognosis. Am J Surg Pathol 28(2):198–206

    Article  PubMed  Google Scholar 

  • Sartori G, Cavazza A et al (2009) EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors. Am J Clin Pathol 131(4):478–489

    Article  PubMed  CAS  Google Scholar 

  • Scagliotti GV, Parikh P et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26(21):3543–3551

    Article  PubMed  CAS  Google Scholar 

  • Scagliotti G, Hanna N et al (2009a) The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 14(3):253–263

    Article  PubMed  CAS  Google Scholar 

  • Scagliotti GV, Park K et al (2009b) Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaive patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study. Eur J Cancer 45(13):2298–2303

    Article  PubMed  CAS  Google Scholar 

  • Soda M, Choi YL et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448(7153):561–566

    Article  PubMed  CAS  Google Scholar 

  • Srinivasan M, Sedmak D et al (2002) Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol 161(6):1961–1971

    Article  PubMed  CAS  Google Scholar 

  • Suzuki K, Asamura H et al (2002) “Early” peripheral lung cancer: prognostic significance of ground glass opacity on thin-section computed tomographic scan. Ann Thorac Surg 74(5):1635–1639

    Article  PubMed  Google Scholar 

  • Terry J, Leung S et al (2010) Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol 34(12):1805–1811

    Article  PubMed  Google Scholar 

  • Travis WD, Brambilla E et al (2004) Pathology and genetics: tumours of the lung, pleura, thymus and heart. IARC, Lyon

    Google Scholar 

  • Travis WD, Brambilla E et al (2011) International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6(2):244–285

    Article  PubMed  Google Scholar 

  • Wu M, Wang B et al (2003) p63 and TTF-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung. Am J Clin Pathol 119(5):696–702

    Article  PubMed  Google Scholar 

  • Yim J, Zhu LC et al (2007) Histologic features are important prognostic indicators in early stages lung adenocarcinomas. Mod Pathol 20(2):233–241

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mount Sinai Medical Center, One Gustave L. Levy Place, New York, NY, 10128, USA

    Mary Beth Beasley

Authors
  1. Mary Beth Beasley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mary Beth Beasley .

Editor information

Editors and Affiliations

  1. Institute of Lung Diseases, Institutski put 4, Sremska Kamenica, 21204, Serbia

    Branislav Jeremic

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Beasley, M.B. (2011). Pathology of Lung Cancer. In: Jeremic, B. (eds) Advances in Radiation Oncology in Lung Cancer. Medical Radiology(). Springer, Berlin, Heidelberg. https://doi.org/10.1007/174_2011_304

Download citation

  • DOI: https://doi.org/10.1007/174_2011_304

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-19924-0

  • Online ISBN: 978-3-642-19925-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation